Affiliation:
1. V.A. Nasonova Scientific and Research Institute of Rheumatology
Abstract
The development of the modern world is manifested, inter alia, by an increase in the prevalence of obesity and cardiovascular diseases. Treatment of these conditions is associated with the need to prescribe multicomponent therapy, which complicates the control of drug interactions, leads to a decrease in compliance and polypharmacy. A large number of drugs taken in a particular patient dictates the need to search for drugs, the appointment of which contributes to the control of several diseases at once, can be successfully used in patients with reduced renal function, in the presence of cardiovascular diseases. The presented description of a clinical case demonstrates an example of the use of a type 2 sodium glucose cotransporter inhibitor – dapagliflozin in a patient with type 2 diabetes mellitus, chronic kidney disease, chronic heart failure and gout.
Publisher
Non-profit organization Nephrology
Reference40 articles.
1. Instructions for medical use of the drug Forsiga (film-coated tablets, 5 mg, 10 mg). Registration certificate LP-002596 dated 08/21/2014 (reissued on 10/01/2021)
2. Panevin TS, Eliseev MS, Shestakova MV, Nasonov EL. Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout. Therapeutic Archive 2020;92(5):110–118. (In Russ.)]. doi: 10.26442/00403660.2020.05.000633
3. Chung MC, Hung PH, Hsiao PJ et al. Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan. JAMA Netw Open 2021;4(11):e2135353. Published 2021 Nov 1. doi:10.1001/jamanetworkopen.2021.35353
4. Barskova VG, Eliseev MS, Denisov IS, et al. The frequency of metabolic syndrome and concomitant diseases in patients with gout. Data from a multicenter study. Nauchno-prakticheskaya revmatologiya. 2012;50(6):15–18. (In Russ.)
5. Krishnan E, Svendsen K, Neaton JD, et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008;168(10):1104–1110. doi:10.1001/archinte.168.10.1104